Proteasome inhibitor‐associated histiocytoid Sweet's syndrome: Clinical and histological similarities to Nakajo‐Nishimura syndrome suggest a potential mechanism
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17201 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Ryang Cho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Boron Compounds, Glycine, Multiple Myeloma, Proteasome Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Histiocytoid Sweet's syndrome (HSS) is a variant of Sweet's syndrome (SS) that clinically resembles SS but differs histologically by infiltrates, predominantly composed of immature cells of the myeloid lineage. Medications such as proteasome inhibitors have been reported to cause HSS but there has been little discussion on the underlying mechanism. Here we report two cases of HSS associated with a proteasome inhibitor. Both patients were on ixazomib for the treatment of multiple myeloma and presented with acute erythematous plaques on the upper half of the body. Pathological findings were consistent with HSS. Similarities between proteasome inhibitor‐induced HSS and Nakajo‐Nishimura syndrome, an inherited inflammatory disease, can be identified both clinically and histologically, suggesting a potential explanation of the mechanism behind proteasome inhibitor‐associated HSS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
- A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
ORCID-Profile: Ryang Cho, Saeko Nakajima, Naotomo Kambe, Kenji Kabashima
Zitieren
APA
Cho, R., Nakajima, S., Kaku, Y., Tezuka, J., Fujimoto, M., Kambe, N., & Kabashima, K. (2024). Proteasome inhibitor‐associated histiocytoid Sweet's syndrome: Clinical and histological similarities to Nakajo‐Nishimura syndrome suggest a potential mechanism. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17201
Vancouver
Cho R, Nakajima S, Kaku Y, Tezuka J, Fujimoto M, Kambe N, et al. Proteasome inhibitor‐associated histiocytoid Sweet's syndrome: Clinical and histological similarities to Nakajo‐Nishimura syndrome suggest a potential mechanism. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17201
BibTeX
@article{Cho2024,
author = {Cho, Ryang and Nakajima, Saeko and Kaku, Yo and Tezuka, Junko and Fujimoto, Masakazu and Kambe, Naotomo and Kabashima, Kenji},
title = {Proteasome inhibitor‐associated histiocytoid Sweet's syndrome: Clinical and histological similarities to Nakajo‐Nishimura syndrome suggest a potential mechanism},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17201}
}
EUVIMED